(Received for publication December 22, 1981) We report here a total synthesis of nocardicin A. The antibiotic was obtained as a mixture of diastereoisomers that possessed approximately one quarter of the antibacterial activity of the naturally occurring material. The synthesis of nocardicin A can be visualized as a three part problem involving 1) synthesis of the side chain acid containing homoserine linked at the para position to the oxime derivative of phenyl- coupling of the two suitably protected parts of the molecule followed by removal of the protecting groups to give the desired nocardicin A.
B. Synthesis of the Side Chain Acid (Scheme 1)
Carbobenzoxy-(±)-homoserine benzyl ester 16) was coupled with the fluorenyl ester of p-hydroxyphenylglyoxylic acid 27) using diethyl azodicarboxylate and triphenylphosphine to afford compound 3 which was readily converted to the side chain acid 4 by reaction with trifluoroacetic acid and anisole. The protected side chain acid 4 was coupled with the 3-aminonocardicinic acid derivative 10 using EEDQ (ethyl 1,2-dihydro-2-ethoxy-l-quinolinecarboxylate) to give the desired product (11) which was purified by column chromatography. Treatment of compound 11 with hydroxylamine and pyridine at 60°C cleaved the acetate protecting group of the phenol moiety and gave the oxime 12. Catalytic hydrogenation of compound 12 gave nocardicin A (13) as a mixture of diastereoisomers along with some nocardicin B (14) as shown by proton magnetic resonance spectroscopy.
The in vitro activity of the synthetic compound was approximately one quarter of that exhibited by the natural antibiotic as shown in Table 1 . 1,2-Dibenzyl-2-carboxyamino-4-(p-carboxycarbonylphenoxy)-(+)-butyrate (4) A solution of 810 mg of fluorenyl ester (3) dissolved in anisole (1.82 ml) was cooled in an ice bath, and 8 ml of chilled trifluoroacetic acid was added with stirring. After 10 minutes in the cold, the acid was removed by high vacuum evaporation (25°C). Finally, pumping was continued for about-40 minutes while the flask was immersed in room temperature water. The residue was dissolved in 15 ml of ether and extracted with 10 ml of water containing 180 mg of sodium bicarbonate (chilled). Centrifugation was required to separate the phases. 14 mole) was slurried in 250 ml tetrahydrofurar. and 17 ml (0.17 mole) 40% aqueous formaldehyde was added. The resulting solution was stirred overnight at room temperature, evaporated to 100 m] and 350 ml methylene chloride was added. After extraction with water and saturated sodium chloride, the solution was dried over magnesium sulfate and evaporated to give 44 g (100%) of a foam which dried as a glass. 95 g ) was dissolved in 45 ml of dry methylene chloride and 0.55 ml of boron trifluoride etherate was added under strictly anhydrous conditions. After stirring at room temperature for 20 minutes, the mixture was cooled to -40°C and 0.55 g azidoacetyl chloride8) in 5 ml methylene chloride was added under nitrogen over 25 minutes, followed by a solution of 0.76 ml pyridine in 5 ml methylene chloride over 25 minutes. An orange precipitate formed. After stirring for 60 minutes at -40"C and for 100 minutes at 0-5°C, the reaction mixture was washed with 1 N hydrochloric acid, aqueous sodium bicarbonate, water, and saturated sodium chloride. D-2-(3-Amino -2-oxo-l-azetidinyl)-2-(4-acetoxy _phenyl)acetic Acid p-Nitrobenzyl Ester (10) Hydrogen sulfide was bubbled into an ice cold solution of the azido B-lactams (8 & 9) (2 g) and triethylamine (0.64 ml, 4.0 ml) in 120 ml of methylene chloride for 15 minutes. The solution was stirred at room temperature for 1.5 hours then nitrogen was bubbled through the solution for 10 minutes. Evaporation at reduced pressure gave an oil which was redissolved in methylene chloride and again evaporated at reduced pressure. The latter procedure was repeated and the resulting oil was used directly in the next step.
A solution of the side chain acid (4) (2.0 g) the aminonocardicinic acid derivative described above and EEDQ (1.1 g) in 125 ml of methylene chloride was allowed to stand at room temperature overnight. The solution was extracted with cold I N hydrochloric acid, water, saturated sodium bicarbonate solution, water, and brine then dried over magnesium sulfate. The solvent was removed at reduced pressure and the resulting oil was chromatographed on 200 g of silica gel using methylene chloride 5% acetone to afford 3. A solution of compound 11 and 1.0 g of hydroxylamine hydrochloride in 30 ml of ethanol and 30 ml of pyridine was heated at 60°C for 2.5 hours. The mixture was cooled and 100 ml of methylene chloride added. The resulting solution was extracted with two aliquots of I N hydrochloric acid, water, and brine then dried over magnesium sulfate. Removal of the solvent left a glass; yield 2.2 g (100%): The proton magnetic resonance spectrum of this compound was similar to compound 11 except the acetyl was no longer present.
Anal. Calcd. The protected nocardicin derivative 12 (1.1 g) was dissolved in a solution of 20 ml of methanol, 10 ml of tetrahydrofuran and 10 ml of water. Palladium on carbon (10%) (0.6 g) was added and the mixture was hydrogenated at atmospheric pressure for 2 hours. An additional 0.3 g of 10% palladium on carbon was added and hydrogenation was continued for another 0.5 hour. The catalyst was filtered and the filtrate evaporated to dryness and the resulting solid was dissolved in a solution of 10 ml of water and 5 ml of methanol by adding 1 N sodium hydroxide to pH 9. The solution was treated with decolorizing carbon, filtered and the filtrate was adjusted to pH 3.5 with 4 N HCI. The resulting solid was collected and dried to afford 0.25 g (39 %). Proton magnetic resonance spectroscopy indicated that this material contained both nocardicin A and B with the former as the major product. Bioassay showed about 25 % of the potency of an authentic sample of nocardicin A (see Table 1 We also thank Mrs. N. KUCK and staff for the bioassays included in this report.
